Bayer (BAYN.DE) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $55.45B | Exchange | XETRA |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | DE | CEO | William N. Anderson |
| IPO Date | 1996-12-16 | CAGR | 1.81% |
| Employees | 87,830 | Website | www.bayer.com |
| Div. Yield | 0.26% | Payout Ratio | -8% |
| Buy Back Yield | 0.03% | Total Yield | 0.29% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $49.34B | P/E | 10.08 | Forward P/E | 10.05 | PEG | — |
| P/S | 0.92 | P/B | 1.4 | P/CF | 9.99 | P/FCF | 28.58 |
| Sales | $52.49B | Sales 1Y | -1.73% | Sales 3Y | -6.85% | Sales 5Y | 8.86% |
| EPS | $5.6 | EPS 1Y | -49.43% | EPS 3Y | -218.92% | EPS 5Y | -35.53% |
| Sales QoQ | -18.9% | EPS QoQ | -91.81% | Sales QoQ Avg | 1.66% | EPS QoQ Avg | 103.61% |
| Gross Margin | 59.05% | Operating Margin | 13.67% | Profit Margin | -3.83% | ROCE | 8.27% |
| ROA | -2% | ROE | -6% | Altman Z Score | 0.85 | Piotroski Score | 3 |
| Current Ratio | 1.04 | Quick Ratio | 0.67 | Cash Ratio | 0.13 | Op. CF Ratio | 0.02 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | 2.43 | Inventory Turnover | 1.55 | Asset Turnover | 0.42 | Receivables Turnover | 3.04 |
| Enterprise Value | $49.34B | P/E Ratio | 10.08 |
| Forward P/E | 10.05 | PEG Ratio | — |
| P/S Ratio | 0.92 | P/B Ratio | 1.4 |
| P/CF Ratio | 9.99 | P/FCF Ratio | 28.58 |
| EPS | $5.6 | EPS Growth 1Y | -49.43% |
| EPS Growth 3Y | -218.92% | EPS Growth 5Y | -35.53% |
| Revenue Growth 1Y | -1.73% | Gross Margin | 0.59% |
| Operating Margin | 0.14% | Profit Margin | -0.04% |
| ROE | -0.06% | ROA | -0.02% |
| ROCE | 0.08% | Current Ratio | 1.04 |
| Quick Ratio | 0.67 | Cash Ratio | 0.13 |
| Debt/Equity | — | Interest Coverage | 2.43 |
| Altman Z Score | 0.85 | Piotroski Score | 3 |
Bayer (BAYN.DE) valuation & financials
Bayer (BAYN.DE) has a market capitalization of 55.45B EUR and trades at a price-to-earnings ratio of 10.1. It operates in the Healthcare sector (Drug Manufacturers - General).
Bayer's revenue grew -1.7% over the last year.
Bayer's next earnings report is scheduled for November 3, 2026; analysts estimate EPS of 0.58 EUR. Check the earnings calendar to see all companies reporting this week.
Bayer (BAYN.DE) — frequently asked questions
When does Bayer (BAYN.DE) report earnings next?
Bayer is expected to report earnings on November 3, 2026. Analysts estimate EPS of 0.58 EUR.
What is Bayer's market cap?
Bayer (BAYN.DE) has a market capitalization of 55.45B EUR.
What is BAYN.DE's P/E ratio?
Bayer trades at a price-to-earnings ratio of 10.1, with trailing twelve-month EPS of 5.60 EUR.
How fast is Bayer growing?
Bayer's revenue grew -1.7% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)